My Crossword Maker Logo
Powered by BrightSprout
Save Status:
or to save your progress. The page will not refresh.
Controls:
SPACEBAR SWITCHES TYPING DIRECTION
Answer Key:
Edit a Copy:
Make Your Own:
Crucigrama Sopa de Letras Hoja de Trabajo
Calificar este Puzzle:
Log in or sign up to rate this puzzle.

Latest and Greatest in Breast Cancer treatment

Horizontales
this PARP inhibitor was studied in the OlypiAD trial in patients with BRCA mutation and HER2-negative metastatic breast cancer
Neratinib requires dose adjustment for severe blank impairment
how many genes are tested in the Oncotype DX gene based assay
Blank positive tumors showed the greatest median OS in the Impassion 130 trial
these Jewish women are a special population having a much higher occurrence of BRCA mutations
the primary endpoint of the ExteNET trial
this prognositic tool estimates 10-year risk of cancer-related mortality or relapse without systemic adjuvant therapy
This tyrosine kinase inhibitor received FDA approval based on the ExteNET trial
Blank 130 was the trial in locally advanced or metastatic triple-negative breast comparing atezolizumab + albumin-bound paclitaxel to placebo + albumin-bound paclitaxel
this trial compared capecitabine vs placebo in patients with triple-negative breast cancer and invasive residual disease following standard neoadjuvant treatment
Talazoparib is dose reduced based on blank impairment
Verticales
Neratinib works by blocking the blank binding site on the intracellular domain of HER2
This trial investigated the addition of pertuzumab to adjuvant trastuzumab and chemotherapy.
we are seeing this drug recommended in HER2 positive patients with residual disease after neo-adjuvant chemo based on the KATHERINE trial
this drug received approval based on the EMBRACA trial
this gene-based assay screens for expression of 70 genes
Name of the Enhertu trial
in this trial Mammaprint was used to assess genomic risk and Adjuvant!Online was used to assess clinical risk
Although relatively rare in the general population this mutation increases the risk of developing breast cancer.